tyvyt sale beat expect tyvyt sale reach
mn higher expect move forward
expect increas sale remain month therefor
increas full year tyvyt sale bn bn
think except sale number due better hospit
access doctor/pati awar ndrl
afford price cut strong endors lilli brand
effect commerci forc headcount
becom blockbust drug label expans expect
innov submit five tyvyt nda nsclc
escc sinc nsclc two common cancer
type china expect approv drive tyvyt sale
bn
maintain outperform lift target price
increas revenu estim
factor better-than-expect sale outperform
rate base innov lead posit drug
develop commercialis rich pipelin multipl near-
particularli impress
april innov announc drug tyvyt sale
reach mn higher expect
sale
significantli reduc feb partial recov
although monthli sale data releas estim
tyvyt sale jan/feb/mar mn move
forward expect see increas sale remain month
therefor increas full year tyvyt sale bn
think except sale number due better hospit
access doctor/pati awar becam first
drug cover ndrl nation drug reimburs list
better afford price cut with/without pap patient
assist program strong endors lilli brand tyvyt
domest drug mnc co-brand
effect commerci forc headcount till tyvyt
sale dtp pharmaci expect hospit sale pick
futur also expect see drug list
ndrl player would see commerci valu
ndrl innov exampl
becom blockbust drug label expans
addit first approv indic chl classic hodgkin
lymphoma tyvyt undergo clinic trial across china/th us
estimate pot chg tp
number share mn
chg prev ep
registr pivot trial studi
non-squam nsclc met primari endpoint
interim analysi thu would go straight nda file stage
studi squamou nsclc studi
squamou nsclc studi
complet patient enrol on-going ph studi expect
innov submit five tyvyt nda non-squam
escc sinc nsclc two common
cancer type china incid respect
china expect approv bring larg market opportun
drive tyvyt sale bn
figur on-going trial tyvyt
maintain outperform lift tp
increas revenu estim reduc
net loss factor better-than-expect
sale outperform rate base innov lead
posit drug develop commercialis rich pipelin
drug multipl near-term catalyst nda approv nda
submiss key readout
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau univers toronto compani mention price
fei zheng jason liu certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part compens
directli indirectli relat specif recommend view express report
price rate histori innov
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
